Protocol for Modifying Ovarian Cancer Organoids
Author Information
Author(s): Hierlmayer Sophia, Hladchenko Liliia, Reichenbach Juliane, Klein Christoph, Mahner Sven, Trillsch Fabian, Kessler Mirjana, Chelariu-Raicu Anca
Primary Institution: Ludwig-Maximilians-University Munich
Hypothesis
The knockdown of the MACC1 oncogene in high-grade serous ovarian cancer organoids will provide insights into its role in disease progression.
Conclusion
The study successfully established a stable knockdown of the MACC1 oncogene in ovarian cancer organoids, demonstrating its potential as a therapeutic target.
Supporting Evidence
- The MACC1 knockdown was maintained for over 3 months in culture.
- Stable knockdown of MACC1 led to a significant decrease in its expression levels.
- Validation of knockdown efficacy was performed using qPCR and Western Blot techniques.
Takeaway
Researchers created a way to change the genes in cancer cells grown in the lab, which helps them understand how cancer works and find new treatments.
Methodology
The study involved lentiviral transduction to knock down the MACC1 gene in patient-derived ovarian cancer organoids, followed by validation through qPCR and Western Blot.
Potential Biases
The study may be influenced by the specific characteristics of the organoid lines used.
Limitations
The transduction process can cause stress to the organoids, potentially affecting their growth and viability.
Participant Demographics
Organoids were derived from chemo-naive, primary, advanced ovarian cancer tumor tissue from patients.
Statistical Information
P-Value
0.0022
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website